Two Sigma Investments LP Sells 12,471 Shares of HUTCHMED (China) Limited (NASDAQ:HCM)

Two Sigma Investments LP reduced its stake in HUTCHMED (China) Limited (NASDAQ:HCM) by 17.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,516 shares of the company’s stock after selling 12,471 shares during the quarter. Two Sigma Investments LP’s holdings in HUTCHMED were worth $843,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in HCM. Blue Trust Inc. boosted its holdings in HUTCHMED by 99.9% in the 4th quarter. Blue Trust Inc. now owns 7,068 shares of the company’s stock valued at $102,000 after purchasing an additional 3,532 shares during the period. XY Capital Ltd bought a new position in shares of HUTCHMED during the fourth quarter valued at $673,000. Summit Trail Advisors LLC raised its stake in HUTCHMED by 14.4% during the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company’s stock worth $189,000 after buying an additional 1,647 shares during the last quarter. ABC Arbitrage SA bought a new position in HUTCHMED during the fourth quarter worth $500,000. Finally, OLD Mission Capital LLC bought a new stake in HUTCHMED in the fourth quarter valued at $230,000. 8.82% of the stock is owned by institutional investors.

HUTCHMED Stock Up 0.6%

NASDAQ:HCM opened at $15.35 on Friday. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07. The company has a 50-day moving average price of $14.05 and a 200-day moving average price of $14.80. HUTCHMED has a 12 month low of $11.51 and a 12 month high of $21.50.

Analyst Ratings Changes

Several research firms recently weighed in on HCM. HSBC cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a report on Tuesday, May 13th. Wall Street Zen raised shares of HUTCHMED from a “buy” rating to a “strong-buy” rating in a research report on Friday.

HUTCHMED Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.